Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | APP | P05067 | 3/20 | 0.56 |
| ▸ | TTR | P02766 | 1/20 | 0.56 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.54 |
| ▸ | CA12 | O43570 | 1/20 | 0.53 |
| ▸ | CA1 | P00915 | 1/20 | 0.53 |
| ▸ | CA2 | P00918 | 1/20 | 0.53 |
| ▸ | TYR | P14679 | 1/20 | 0.53 |
| ▸ | CA7 | P43166 | 1/20 | 0.53 |
| ▸ | CA9 | Q16790 | 1/20 | 0.53 |
| ▸ | CA14 | Q9ULX7 | 1/20 | 0.53 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.52 |
| ▸ | KDM4E | B2RXH2 | 6/20 | 0.51 |
| ▸ | MAPT | P10636 | 5/20 | 0.51 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.51 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.51 |
| ▸ | HTT | P42858 | 2/20 | 0.51 |
| ▸ | JAK2 | O60674 | 1/20 | 0.51 |
| ▸ | GAA | P10253 | 1/20 | 0.51 |
| ▸ | FDPS | P14324 | 1/20 | 0.49 |
| ▸ | PRKCI | P41743 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL972204 | 1.00 | APP (0.56) | APPTTRPTPN1CA12CA1 | |
| SCHEMBL19185722 | 0.87 | APP (0.55) | APPTTRPTPN1CA12CA1 | |
| SCHEMBL9412607 | 0.84 | NPSR1 (0.50) | APPTTRPTPN1CA12CA1 | |
| SCHEMBL5225706 | 0.84 | TTR (0.63) | APPTTRPTPN1CA12CA1 | |
| SCHEMBL8289391 | 0.82 | HDAC6 (0.51) | PRKCI | |
| SCHEMBL11222387 | 0.81 | APP (0.73) | APPTTRPTPN1CA12CA1 | |
| SCHEMBL2847487 | 0.81 | TTR (0.59) | APPTTRPTPN1CA12CA1 | |
| SCHEMBL29913987 | 0.81 | APP (0.73) | APPTTRPTPN1CA12CA1 | |
| SCHEMBL2847488 | 0.81 | TTR (0.59) | APPTTRPTPN1CA12CA1 | |
| SCHEMBL11222383 | 0.81 | APP (0.73) | APPTTRPTPN1CA12CA1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2626354-A1 | Viral polymerase inhibitors | Boehringer Ingelheim International GmbH (DE) | 2013-08-14 | — | — | EP | disclosed |
| EP-1718608-B1 | VIRAL POLYMERASE INHIBITORS | BOEHRINGER INGELHEIM INT (DE) | 2013-07-17 | — | — | EP | disclosed |
| US-8030309-B2 | Viral polymerase inhibitors | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2011-10-04 | — | — | US | disclosed |
| US-7879851-B2 | such as (E)-3-[2-(1-{[2-(5-Bromopyrimidin-2-yl)-3-cyclopentyl-1-methyl-1H-indole-6-carbonyl]-amino}-cyclobutyl)-3-methyl-3H-benzoimidazol-5-yl]-acrylic Acid, used for the treatment of hepatitis C virus infections | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2011-02-01 | — | — | US | disclosed |
| US-20110015203-A1 | Viral Polymerase Inhibitors | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2011-01-20 | — | — | US | disclosed |
| US-7582770-B2 | Viral polymerase inhibitors | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2009-09-01 | — | — | US | disclosed |
| US-20090170859-A1 | Viral Polymerase Inhibitors | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2009-07-02 | — | — | US | disclosed |
| EP-1718608-A1 | VIRAL POLYMERASE INHIBITORS | Boehringer Ingelheim International GmbH (DE) | 2006-11-08 | — | — | EP | disclosed |
| US-20050222236-A1 | Viral polymerase inhibitors | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2005-10-06 | — | — | US | disclosed |
| WO-2005080388-A1 | VIRAL POLYMERASE INHIBITORS | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2005-09-01 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090170859-A1 | Viral Polymerase Inhibitors | POLR2A, POLR1E, RPP30 | APP 2182/4885TTR 645/4885PTPN1 1912/4885 |
| US-20050222236-A1 | Viral polymerase inhibitors | POLR2A, POLR1E, RPP30 | APP 2182/4885TTR 645/4885PTPN1 1912/4885 |
| US-20110015203-A1 | Viral Polymerase Inhibitors | POLR2A, POLR1E, RPP30 | APP 2182/4885TTR 645/4885PTPN1 1912/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.